<html><body> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation of technical requirements for registration of pharmaceuticals for human use   
 ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>  
 
 impurities:  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> q3c(r5)   
 current step 4 version dated 4 february 2011 parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> dated 17 july 1997 (revised pde for thf and nmp dated september 2002  and october 2002 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/150">incorporated</a></span> in core <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> in  november 2005 and revised pde for cumene <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/150">incorporated</a></span> in core <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> in february 2011)  
 
 
 
 
  
 this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> has been developed by the appropriate ich expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group and has been subject to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span> by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties, in accordance with the ich 
process. at step 4 of the process the final draft is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption to the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/665"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/909"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4060">european</a></span></a></span></a></span> union</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japan</a></span> and usa.  q3c(r5) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> history first codification history date new codification parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>: impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> q3c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 6 november 1996 q3c q3c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. 17 july 1997 q3c revision of the pde <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for thf <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contained</a></span> in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> q3c(m) for thf permissible daily exposure (pde) for tetrahydrofuran (thf): revision of pde based on new <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicological</a></span> data. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee of the new pde for thf under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 20 july 2000 in q3c(r1) q3c(m) for thf <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> 
bodies. 12 september 2002 in q3c(r1) revision of pde <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for nmp <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contained</a></span> in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> q3c(m) for nmp permissible daily exposure (pde) for n-methylpyrrolidone (nmp): revision of pde based on new <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicological</a></span> data. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee of the revision under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 20 july  2000 in q3c(r2) q3c(m) for nmp <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> 
bodies. 12 september 2002 in q3c(r2) q3c(m) for nmp corrigendum to calculation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formula</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approved</a></span> by the steering committee. 28 october 2002 in q3c(r3) q3c, q3c(m) for thf and q3c(m) for nmp the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is now renamed q3c(r3) as the two updates (pde for n-methylpyrrolidone and pde for tetrahydrofuran) and the corrigendum of the update for nmp have been added to the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>.   november 2005 q3c(r3) parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>: impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> q3c(r4) update of table 2, table 3 and appendix 1 to reflect the revision of the pdes for n-methylpyrrolidone and 
tetrahydrofuran. february 2009 q3c(r4) revision of pde <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for cumene <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contained</a></span> in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> pde for cumene permissible daily exposure (pde) for cumene: revision of pde based on new <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicological</a></span> data. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 26 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1813">march</a></span> 2010 in q3c(r5)  current step 4 version q3c(r5) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> of the pde for cumene by the steering committee under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. 
the pde for cumene <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> has been integrated as part iv 
in the core q3c(r4) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> which was then renamed 
q3c(r5). the table 2, table 3 and appendix 1 have been updated to reflect the revision of the pde for cumene. 4 february 2011 q3c(r5)  i impurities:  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>  table of contents  part i: 1.introduction .................................................................................................... 12.scope of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> .............................................................................. 13.general principles ...................................................................................... 23.1classification of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> by risk <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span> ........................................ 23.2methods for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> exposure limits ............................................................. 23.3options for describing limits of class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> .................................................. 33.4analytical procedures ............................................................................................... 43.5reporting levels of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> ....................................................................... 44.limits of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> .................................................................... 54.1solvents to be avoided ............................................................................................. 54.2solvents to be limited .............................................................................................. 64.3solvents with low toxic potential ........................................................................... 74.4solvents for which no adequate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicological</a></span> data was found ............................ 8glossary ....................................................................................................................... 9appendix 1. list of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> included in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> ............ 10appendix 2. additional background ........................................................ 14a2.1environmental <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulation</a></span> of organic volatile <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> ...................................... 14a2.2residual <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in pharmaceuticals ................................................................... 14appendix 3. methods for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> exposure limits ............. 15part ii: pde for tetrahydrofuran ............................................................................. 18part iii: pde for n-methylpyrrolidone (nmp) ....................................................... 20part iv: pde for cumene ...................................................................................................... 22  1 part i: impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> having reached step 4 of the ich process at the ich steering committee meeting on 17 july 1997, this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption  to the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties to ich  1. introduction the objective of this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommend</a></span> acceptable amounts for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in pharmaceuticals for the safety of the patient. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommends</a></span> use of less toxic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> and describes levels considered to be toxicologically 
acceptable for some <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in pharmaceuticals are defined here as <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3817">organic volatile chemicals</a></span> that are used or produced in the manufacture of drug substances or excipients, or in the preparation of drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> are not completely removed by 
practical manufacturing techniques. appropriate selection of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> for the 
synthesis of drug substance may enhance the yield, or determine characteristics such 
as crystal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span>, purity, and solubility. therefore, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> may sometimes be a critical parameter in the synthetic process. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> does not address <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> deliberately used as excipients nor does it address solvates. however, the content of 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in such <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be evaluated and justified. since there is no <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4455">therapeutic</a></span> benefit from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>, all <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> should be removed to the extent possible to meet <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> specifications, good 
manufacturing practices, or other quality-based requirements. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contain</a></span> no higher levels of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> than can be supported by safety data. some <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> that are known to cause unacceptable toxicities (class 1, table 1) should be avoided in  the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> of drug substances, excipients, or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> unless their use can be strongly justified in a risk-benefit <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span>. some <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2944">associated</a></span> with less severe toxicity (class 2, table 2) should be limited in order to protect patients from potential adverse effects. ideally, less toxic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> (class 3, table 3) should be used where practical. the complete list of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> included in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is given in appendix 1. the lists are not exhaustive and other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> can be used and later added to the lists. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> limits of class 1 and 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> or classification of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> may change as new safety data becomes available. supporting safety data in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> application for a new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containing</a></span> a new <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> may be based on concepts in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> or the concept of qualification of impurities as expressed in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for drug substance (q3a, impurities in new drug substances) or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> (q3b, impurities in new drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>), or all three guidelines.  2. scope of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in drug substances, excipients, and in drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> are within the scope of this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. therefore, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be performed for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 
when <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> or purification processes are known to result in the presence of such 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>. it is only necessary to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> that are used or produced in the 
manufacture or purification of drug substances, excipients, or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. although 
manufacturers may choose to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, a cumulative method may be used to calculate the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> levels in the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> from the levels in the ingredients used to produce the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. if the calculation results in a level impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 2 equal to or below that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>, no <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> need be considered. if, however, the calculated level is above the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> level, the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> to ascertain whether the 
formulation process has reduced the relevant <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> level to within the acceptable amount. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should also be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> if a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> is used during its manufacture. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> does not apply to potential new drug substances, excipients, or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> used during the clinical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2914">research</a></span> stages of development, nor does it apply to 
existing <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketed</a></span></a></span> drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> applies to all dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> and routes of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8542">administration</a></span>. higher levels of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> may be acceptable in certain cases such as short term (30 days or less) or topical application. justification for these levels should be made on a case by case basis. see appendix 2 for additional background <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> related to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>. 3. general principles 3.1 classification of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> by risk <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span> the term "tolerable daily intake" (tdi) is used by the international program on chemical safety (ipcs) to describe exposure limits of toxic chemicals and "acceptable daily intake" (adi) is used by the world health organization (who) and other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span> and international health authorities and institutes. the new term "permitted daily exposure" (pde) is defined in the present <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> as a pharmaceutically acceptable intake of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> to avoid confusion of differing values for adi's of the same substance. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span> in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> are listed in appendix 1 by common names and structures. they were evaluated for their possible risk to human health and placed into one of three classes as follows: class 1 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>:  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> to be avoided known human carcinogens, strongly suspected human carcinogens, and environmental hazards. class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>:  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> to be limited non-genotoxic animal carcinogens or possible causative agents of other irreversible toxicity such as neurotoxicity or teratogenicity. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> suspected of other significant but reversible toxicities. class 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>:  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> with low toxic potential <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> with low toxic potential to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5281">man</a></span>; no health-based exposure limit is needed. class 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> have pdes of 50 mg or more per day.  3.2 methods for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> exposure limits the method used to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> permitted daily exposures for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> is presented in appendix 3. summaries of the toxicity data that were used to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> limits are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/667"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1745">published</a></span></a></span> in pharmeuropa, vol. 9, no. 1, supplement, april 1997. impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 3 3.3 options for describing limits of class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> two options are available when setting limits for class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>.  option 1:  the concentration limits in ppm <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">stated</a></span> in table 2 can be used. they were calculated using equation (1) below by assuming a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> mass of 10 g administered daily. concentration (ppm)1000 x pdedose   (1) here, pde is given in terms of mg/day and dose is given in g/day. these limits are considered acceptable for all substances, excipients, or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. therefore this option may be applied if the daily dose is not known or fixed. if all 
excipients and drug substances in a formulation meet the limits given in option 1, 
then these components may be used in any proportion. no further calculation is 
necessary provided the daily dose does not exceed 10 g. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> that are 
administered in doses greater than 10 g per day should be considered under option 2. option 2: it is not considered necessary for each component of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> to comply with the limits given in option 1. the pde in terms of mg/day as <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">stated</a></span> in table 2 can be used with the known maximum daily dose and equation (1) above to determine the concentration of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> allowed in drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. such limits 
are considered acceptable provided that it has been demonstrated that the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> has been reduced to the practical minimum. the limits should be realistic in relation to analytical precision, manufacturing capability, reasonable variation in the manufacturing process, and the limits should reflect contemporary manufacturing 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standards</a></span>.  option 2 may be applied by adding the amounts of a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> present in each of the components of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. the sum of the amounts of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> per day 
should be less than that given by the pde.  consider an example of the use of option 1 and option 2 applied to acetonitrile in a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. the permitted daily exposure to acetonitrile is 4.1 mg per day; thus, the option 1 limit is 410 ppm. the maximum administered daily mass of a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is 5.0 g, and the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contains</a></span> two excipients. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3122">composition</a></span> of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> and the calculated maximum content of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> acetonitrile are given in the 
following table. component amount in formulation acetonitrile content daily exposure drug substance 0.3 g 800 ppm 0.24 mg excipient 1 0.9 g 400 ppm 0.36 mg 
excipient 2 3.8 g 800 ppm 3.04 mg 
drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> 5.0 g 728 ppm 3.64 mg excipient 1 meets the option 1 limit, but the drug substance, excipient 2, and drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> do not meet the option 1 limit. nevertheless, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> meets the option 2 limit of 4.1 mg per day and thus conforms to the recommendations in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 4 consider another example using acetonitrile as <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>. the maximum administered daily mass of a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is 5.0 g, and the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contains</a></span> two excipients. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3122">composition</a></span> of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> and the calculated maximum content 
of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> acetonitrile are given in the following table. component amount in formulation acetonitrile content daily exposure drug substance 0.3 g 800 ppm 0.24 mg excipient 1 0.9 g 2000 ppm 1.80 mg 
excipient 2 3.8 g 800 ppm 3.04 mg 
drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> 5.0 g 1016 ppm 5.08 mg in this example, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> meets neither the option 1 nor the option 2 limit according to this summation. the manufacturer could <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> to 
determine if the formulation process reduced the level of acetonitrile. if the level of acetonitrile was not reduced during formulation to the allowed limit, then the 
manufacturer of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should take other steps to reduce the amount of 
acetonitrile in the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. if all of these steps fail to reduce the level of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>, in exceptional cases the manufacturer could provide a summary of efforts 
made to reduce the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> level to meet the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> value, and provide a risk-
benefit analysis to support allowing the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> to be utilised with <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> at a higher level.  3.4 analytical procedures <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> are typically determined using chromatographic techniques such as <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1139">gas</a></span> chromatography. any harmonised procedures for determining levels of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> as described in the pharmacopoeias should be used, if feasible. otherwise, manufacturers would be free to select the most appropriate validated analytical procedure for a particular application. if only class 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> are present, a non-specific method such as <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> on drying may be used. validation of methods for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> should conform to ich guidelines text on validation of analytical procedures and extension of the ich text on validation of analytical procedures. 3.5 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reporting</a></span> levels of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> manufacturers of pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> need certain <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> about the content of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in excipients or drug substances in order to meet the criteria of this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. the following <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statements</a></span> are given as acceptable examples of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> that could be provided from a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1078"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2292">supplier</a></span></a></span> of excipients or drug substances to a pharmaceutical manufacturer. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1078"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2292">supplier</a></span></a></span> might choose one of the following as 
appropriate:  only class 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> are likely to be present. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/367">loss</a></span> on drying is less than 0.5%.  only class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> x, y, ... are likely to be present. all are below the option 1 limit. (here the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1078"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2292">supplier</a></span></a></span> would name the class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> represented by x, y, ...)  only class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> x, y, ... and class 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> are likely to be present. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> are below the option 1 limit and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> class 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> are below 0.5%.  impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 5 if class 1 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> are likely to be present, they should be identified and quantified.  "likely to be present" refers to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> used in the final manufacturing step and to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> that are used in earlier manufacturing steps and not removed consistently by a validated process.  if <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> of class 2 or class 3 are present at greater than their option 1 limits or 0.5%, respectively, they should be identified and quantified.  4. limits of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 4.1 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> to be avoided <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in class 1 should not be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span> in the manufacture of drug substances, excipients, and drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> because of their unacceptable toxicity or their 
deleterious environmental effect. however, if their use is unavoidable in order to 
produce a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> with a significant <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4455">therapeutic</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4383">advance</a></span>, then their levels should be restricted as shown in table 1, unless otherwise justified. 1,1,1-trichloroethane is included in table 1 because it is an environmental hazard. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">stated</a></span> limit of 1500 ppm is based on a review of the safety data. table 1. class 1 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> that should be avoided). <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>  concentration limit (ppm) concern benzene 2 carcinogen <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5261">carbon</a></span> tetrachloride 4 toxic and environmental hazard 1,2-dichloroethane  5 toxic 
1,1-dichloroethene 8 toxic 1,1,1-trichloroethane 1500 environmental hazard impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 6 4.2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> to be limited <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in table 2 should be limited in pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> because of their inherent toxicity. pdes are given to the nearest 0.1 mg/day, and concentrations are given to the nearest 10 ppm. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">stated</a></span> values do not reflect the necessary analytical precision of determination. precision should be determined as part of the validation of the method. table 2. class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>  pde (mg/day) concentration limit (ppm) acetonitrile 4.1 410 chlorobenzene 3.6 360 chloroform 0.6 60 
cumene1 0.7 70 cyclohexane 38.8  3880 1,2-dichloroethene 18.7 1870 dichloromethane 6.0 600 1,2-dimethoxyethane 1.0 100 n,n-dimethylacetamide 10.9 1090 n,n-dimethylformamide 8.8 880 
1,4-dioxane  3.8 380 2-ethoxyethanol 1.6 160 ethyleneglycol 6.2 620 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formamide</a></span> 2.2 220 hexane 2.9 290 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1893">methanol</a></span> 30.0 3000 2-methoxyethanol 0.5 50 methylbutyl ketone 0.5 50 methylcyclohexane 11.8 1180 n-methylpyrrolidone2  5.3  530 nitromethane 0.5 50 pyridine  2.0 200 sulfolane 1.6 160                                                  1 the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> included for cumene reflects that included in the revision of pde <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for cumene which reached step 4 in february 2011 and was subsequently <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/150">incorporated</a></span> into the core <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. see part iv (pages 22-25).  2 the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> included for n-methylpyrrolidone reflects that included in the revision of pde <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for nmp which reached step 4 in september 2002 (two mistyping corrections made in october 2002), and was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/150">incorporated</a></span> into the core <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> in november 2005. see part iii (pages 20-21).  impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 7 tetrahydrofuran3 7.2 720 tetralin 1.0 100 toluene 8.9 890 1,1,2-trichloroethene 0.8 80 xylene* 21.7 2170 *usually 60% m-xylene, 14% p-xylene, 9% o-xylene with 17% ethyl benzene 4.3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> with low toxic potential <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in class 3 (shown in table 3) may be regarded as less toxic and of lower risk to human health. class 3 includes no <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> known as a human health hazard at levels normally accepted in pharmaceuticals. however, there are no long-term toxicity 
or carcinogenicity studies for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5281">many</a></span> of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in class 3. available data indicate 
that they are less toxic in acute or short-term studies and negative in genotoxicity studies. it is considered that amounts of these <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> of 50 mg per day or 
less (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/242">corresponding</a></span> to 5000 ppm or 0.5% under option 1) would be acceptable without justification. higher amounts may also be acceptable provided they are realistic in relation to manufacturing capability and good manufacturing practice. table 3. class 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> which should be limited by gmp or other quality-based requirements. acetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> heptane acetone <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1510">isobutyl</a></span> acetate 
anisole isopropyl acetate 
1-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3768">butanol</a></span> methyl acetate 
2-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3768">butanol</a></span> 3-methyl-1-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3768">butanol</a></span> butyl acetate methylethyl ketone 
tert-butylmethyl ether methylisobutyl ketone dimethyl sulfoxide 2-methyl-1-propanol <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/890">ethanol</a></span> pentane 
ethyl acetate 1-pentanol 
ethyl ether 1-propanol ethyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formate</a></span> 2-propanol 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formic</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> propyl acetate                                                  3 the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> included for tetrahydrofuran reflects that included in the revision of pde <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for thf which reached step 4 in september 2002, and was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/150">incorporated</a></span> into the core <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> in november 2005. see part ii (pages 18-19). impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 8 4.4 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> for which no adequate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicological</a></span> data was found the following <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> (table 4) may also be of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1476">interest</a></span> to manufacturers of excipients, drug substances, or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. however, no adequate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicological</a></span> 
data on which to base a pde was found. manufacturers should supply justification for 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> levels of these <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. table 4. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> for which no adequate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicological</a></span> data was found.  1,1-diethoxypropane methylisopropyl ketone  1,1-dimethoxymethane methyltetrahydrofuran 2,2-dimethoxypropane <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2366"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3771">petroleum</a></span></a></span> ether 
isooctane trichloroacetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> 
isopropyl ether trifluoroacetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 9 glossary genotoxic carcinogens:   carcinogens which produce <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5104">cancer</a></span> by affecting genes or chromosomes. loel:   abbreviation for lowest-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> effect level. lowest-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> effect level:  the lowest dose of substance in a study or group of studies that produces biologically significant increases in frequency or severity of any effects in the exposed humans or animals.  modifying factor:   a factor determined by professional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1537">judgment</a></span> of a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicologist</a></span> and applied to bioassay data to relate that data safely to humans. neurotoxicity:   the ability of a substance to cause adverse effects on the nervous system. noel:   abbreviation for no-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span>-effect level. no-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span>-effect level:  the highest dose of substance at which there are no biologically significant increases in frequency or severity of any effects in the exposed humans or animals. pde:   abbreviation for permitted daily exposure. permitted daily exposure:   the maximum acceptable intake per day of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> in pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. reversible toxicity:   the occurrence of harmful effects that are caused by a substance and which disappear after exposure to the substance ends. strongly suspected human carcinogen:  a substance for which there is no <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/838">epidemiological</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4434">evidence</a></span> of carcinogenesis but there are positive genotoxicity data and clear <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4434">evidence</a></span> of carcinogenesis in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodents</a></span>. teratogenicity:   the occurrence of structural malformations in a developing fetus when a substance is administered during pregnancy. impurities:  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 10 appendix 1. list of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> included in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> other names structure class acetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> ethanoic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> ch3cooh class 3 acetone 2-propanone  propan-2-one ch3coch3 class 3 acetonitrile  ch3cn class 2 anisole methoxybenzene och3 class 3 benzene benzol  class 1 1-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3768">butanol</a></span> n-butyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3768">butan</a></span>-1-ol ch3(ch2)3oh class 3 2-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3768">butanol</a></span> sec-butyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3768">butan</a></span>-2-ol ch3ch2ch(oh)ch3 class 3 butyl acetate acetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> butyl ester ch3coo(ch2)3ch3 class 3 tert-butylmethyl ether 2-methoxy-2-methyl- propane (ch3)3coch3 class 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5261">carbon</a></span> tetrachloride tetrachloromethane ccl4 class 1 chlorobenzene  cl class 2 chloroform trichloromethane chcl3 class 2 
cumene1 isopropylbenzene (1-methyl)ethylbenzene ch(ch3)2 class 2 cyclohexane hexamethylene  class 2 1,2-dichloroethane sym-dichloroethane ethylene dichloride 
ethylene chloride ch2clch2cl class 1                                                  1 the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> included for cumene reflects that included in the revision of pde <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for cumene which reached step 4 in february 2011 and was subsequently <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/150">incorporated</a></span> into the core <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. see part iv (pages 22-25). impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 11 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> other names structure class 1,1-dichloroethene 1,1-dichloroethylene vinylidene chloride h2c=ccl2 class 1 1,2-dichloroethene 1,2-dichloroethylene acetylene dichloride clhc=chcl class 2 dichloromethane methylene chloride ch2cl2 class 2 1,2-dimethoxyethane ethyleneglycol dimethyl ether monoglyme 
dimethyl cellosolve h3coch2ch2och3 class 2 n,n-dimethylacetamide dma ch3con(ch3)2 class 2 n,n-dimethylformamide dmf hcon(ch3)2 class 2 dimethyl sulfoxide methylsulfinylmethane methyl sulfoxide 
dmso (ch3)2so class 3 1,4-dioxane p-dioxane [1,4]dioxane oo class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/890">ethanol</a></span> ethyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span> ch3ch2oh class 3 2-ethoxyethanol cellosolve ch3ch2och2ch2oh class 2 ethyl acetate acetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> ethyl ester ch3cooch2ch3 class 3 ethyleneglycol 1,2-dihydroxyethane 1,2-ethanediol hoch2ch2oh class 2 ethyl ether diethyl ether ethoxyethane 
1,1-oxybisethane ch3ch2och2ch3 class 3 ethyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formate</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formic</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> ethyl ester hcooch2ch3 class 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formamide</a></span> methanamide hconh2 class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formic</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span>  hcooh class 3 heptane n-heptane ch3(ch2)5ch3 class 3 impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 12 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> other names structure class hexane n-hexane ch3(ch2)4ch3 class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1510">isobutyl</a></span> acetate acetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1510">isobutyl</a></span> ester ch3cooch2ch(ch3)2 class 3 isopropyl acetate acetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> isopropyl ester ch3cooch(ch3)2 class 3 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1893">methanol</a></span> methyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span> ch3oh class 2 2-methoxyethanol methyl cellosolve ch3och2ch2oh class 2 methyl acetate acetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> methyl ester ch3cooch3 class 3 3-methyl-1-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3768">butanol</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1510">isoamyl</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span>  isopentyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span> 
3-methylbutan-1-ol (ch3)2chch2ch2oh class 3 methylbutyl ketone 2-hexanone hexan-2-one ch3(ch2)3coch3 class 2 methylcyclohexane cyclohexylmethane ch3 class 2 methylethyl ketone 2-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3768">butanone</a></span> mek 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3768">butan</a></span>-2-one ch3ch2coch3 class 3 methylisobutyl ketone 4-methylpentan-2-one 4-methyl-2-pentanone 
mibk ch3coch2ch(ch3)2 class 3 2-methyl-1-propanol <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1510">isobutyl</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span> 2-methylpropan-1-ol (ch3)2chch2oh class 3 n-methylpyrrolidone 1-methylpyrrolidin-2-one 1-methyl-2-pyrrolidinone nch3o class 2 nitromethane  ch3no2 class 2 pentane n-pentane ch3(ch2)3ch3 class 3 1-pentanol amyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span> pentan-1-ol 
pentyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span> ch3(ch2)3ch2oh class 3 impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 13 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> other names structure class 1-propanol propan-1-ol propyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span> ch3ch2ch2oh class 3 2-propanol propan-2-ol isopropyl <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1134"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1162">alcohol</a></span></a></span> (ch3)2choh class 3 propyl acetate acetic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5035">acid</a></span> propyl ester ch3cooch2ch2ch3 class 3 pyridine  n class 2 sulfolane tetrahydrothiophene 1,1-dioxide soo class 2 tetrahydrofuran2 tetramethylene <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2213">oxide</a></span> oxacyclopentane o class 2 tetralin 1,2,3,4-tetrahydro-naphthalene  class 2 toluene methylbenzene ch3 class 2 1,1,1-trichloroethane methylchloroform ch3ccl3 class 1 1,1,2-trichloroethene trichloroethene hclc=ccl2 class 2 xylene* dimethybenzene xylol ch3ch3 class 2 *usually 60% m-xylene, 14% p-xylene, 9% o-xylene with 17% ethyl benzene                                                  2 the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> included for tetrahydrofuran reflects that included in the revision of pde <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for thf which reached step 4  in september 2002, and was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/150">incorporated</a></span> into the core <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> in november 2005. see part ii (pages 18-19). impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 14 appendix 2. additional background a2.1 environmental <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulation</a></span> of organic volatile <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> several of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> frequently used in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> of pharmaceuticals are listed as toxic chemicals in environmental health criteria (ehc) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1978">monographs</a></span> and 
the integrated risk <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4359">information</a></span> system</a></span> (iris). the objectives of such groups as the 
international programme on chemical safety (ipcs), the united <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2825">environmental 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2844">protection</a></span></a></span> agency (usepa), and the united <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> food and drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8542">administration</a></span> (usfda) include the determination of acceptable exposure levels. the goal is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2844">protection</a></span> of human health and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/831">maintenance</a></span> of environmental integrity against the possible 
deleterious effects of chemicals resulting from long-term environmental exposure. the 
methods involved in the estimation of maximum safe exposure limits are usually based 
on long-term studies. when long-term study data are unavailable, shorter term study 
data can be used with modification of the approach such as use of larger safety factors. the approach described therein relates primarily to long-term or life-time exposure of the general <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/7413">population</a></span> in the ambient environment, i.e., ambient air, food, drinking <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> and other media. a2.2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in pharmaceuticals exposure limits in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> by referring to methodologies and toxicity data described in ehc and iris <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1978">monographs</a></span>. however, some specific 
assumptions about <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> to be used in the synthesis and formulation of pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be taken into <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> exposure limits. they are: 1) patients (not the general <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/7413">population</a></span>) use pharmaceuticals to treat their diseases or for prophylaxis to prevent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1759">infection or disease</a></span>. 2) the assumption of life-time patient exposure is not necessary for most pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> but may be appropriate as a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> hypothesis to reduce risk to human health. 3) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> are unavoidable components in pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> and will often be a part of drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. 4) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> should not exceed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> levels except in exceptional circumstances. 5) data from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicological</a></span> studies that are used to determine acceptable levels for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> should have been generated using appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocols</a></span> such as 
those described for example by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2105">oecd</a></span>, epa, and the fda red book. impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 15 appendix 3. methods for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> exposure limits the gaylor-kodell method of risk <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span> (gaylor, d. w. and kodell, r. l.: linear <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5688">interpolation</a></span> algorithm for low dose <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3135">toxic substance</a></span>. j environ. pathology, 4, 305, 1980) is appropriate for class 1 carcinogenic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>. only in cases where reliable carcinogenicity data are available should extrapolation by the use of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1835">mathematical</a></span> models be applied to setting exposure limits. exposure limits for class 1 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> could be determined with the use of a large safety factor (i.e., 10,000 to 100,000) with respect to the no-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span>-effect level (noel). detection and quantitation of these <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> should be by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">state</a></span>-of-the-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2688">art</a></span> analytical techniques. acceptable exposure levels in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> were <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> by calculation of pde values according to the procedures for setting exposure limits in pharmaceuticals (pharmacopeial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6907">forum</a></span>, nov-dec 1989), and the method adopted by ipcs for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessing</a></span> human <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3730">health risk</a></span> of chemicals (environmental health criteria 170, who, 1994). these methods are similar to those used by the usepa (iris) and the usfda (red book) and others. the method is outlined here to give a better 
understanding of the origin of the pde values. it is not necessary to perform these 
calculations in order to use the pde values tabulated in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 4 of this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span>.   pde is derived from the no-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span>-effect level (noel), or the lowest-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> effect level (loel) in the most relevant animal study as follows:              pde = noel x weight adjustmentf1 x f2 x f3 x f4 x f5 (1)  the pde is derived preferably from a noel. if no noel is obtained, the loel may be used. modifying factors proposed here, for relating the data to humans, are the same kind of "uncertainty factors" used in environmental health criteria (environmental health criteria 170, world health organization, geneva, 1994), and "modifying factors" or "safety factors" in pharmacopeial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6907">forum</a></span>. the assumption of 100% systemic exposure is used in all calculations regardless of route of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8542">administration</a></span>. the modifying factors are as follows: 
f1 = a factor to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> for extrapolation between species f1 = 5 for extrapolation from rats to humans 
f1 = 12 for extrapolation from mice to humans 
f1 = 2 for extrapolation from dogs to humans f1 = 2.5 for extrapolation from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1585">rabbits</a></span> to humans f1 = 3 for extrapolation from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5895">monkeys</a></span> to humans f1 = 10 for extrapolation from other animals to humans f1 takes into <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> the comparative surface area:body weight <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2902">ratios</a></span> for the species concerned and for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5281">man</a></span>. surface area (s) is calculated as:  s = km0.67 (2) in which m = body mass, and the constant k has been taken to be 10. the body weights used in the equation are those shown below in table a3.1. impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 16 f2 = a factor of 10 to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> for variability between individuals a factor of 10 is generally given for all organic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>, and 10 is used consistently in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. f3 = a variable factor to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> for toxicity studies of short-term exposure f3 = 1 for studies that last at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> one half lifetime (1 year for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodents</a></span> or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1585">rabbits</a></span>; 7 years for cats, dogs and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5895">monkeys</a></span>).  f3 = 1 for reproductive studies in which the whole period of organogenesis is covered.  f3 = 2 for a 6-month study in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodents</a></span>, or a 3.5-year study in non-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodents</a></span>.  f3 = 5 for a 3-month study in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodents</a></span>, or a 2-year study in non-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodents</a></span>. f3 = 10 for studies of a shorter duration.  in all cases, the higher factor has been used for study durations between the time points, e.g., a factor of 2 for a 9-month <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodent</a></span> study. f4 = a factor that may be applied in cases of severe toxicity, e.g., non-genotoxic carcinogenicity, neurotoxicity or teratogenicity. in studies of reproductive toxicity, the following factors are used: f4 = 1 for fetal toxicity <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2944">associated</a></span> with maternal toxicity 
f4 = 5 for fetal toxicity without maternal toxicity 
f4 = 5 for a teratogenic effect with maternal toxicity 
f4 = 10 for a teratogenic effect without maternal toxicity f5 = a variable factor that may be applied if the no-effect level was not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> when only an loel is available, a factor of up to 10 could be used <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depending</a></span> on the severity of the toxicity. the weight adjustment assumes an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6617">arbitrary</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/160">adult</a></span> human body weight for either sex of 50 kg. this relatively low weight provides an additional safety factor against the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> weights of 60 kg or 70 kg that are often used in this type of calculation. it is recognized that some <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/160">adult</a></span> patients weigh less than 50 kg; these patients are considered to be accommodated by the built-in safety factors used to determine a pde. if the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> was present in a formulation specifically intended for pediatric 
use, an adjustment for a lower body weight would be appropriate. as an example of the application of this equation, consider a toxicity study of acetonitrile in mice that is summarized in pharmeuropa, vol. 9, no. 1, supplement, april 1997, page s24. the noel is calculated to be 50.7 mg kg-1 day-1. the pde for acetonitrile in this study is calculated as follows: pde = 50.7 mg kg day x 50 kg12 x 10 x 5 x 1 x 1 4.22 mg day-1-1-1 in this example,  f1 = 12 to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> for the extrapolation from mice to humans f2 = 10 to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> for differences between individual humans f3 = 5 because the duration of the study was only 13 weeks 
f4 = 1 because no severe toxicity was encountered 
f5 = 1 because the no effect level was determined impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> 17 table a3.1. values used in the calculations in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span>. rat body weight 425 g mouse respiratory volume 43 l/day pregnant rat body weight 330 g <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1585">rabbit</a></span> respiratory volume 1440 l/day mouse body weight 28 g <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1216">guinea</a></span> pig respiratory volume 430 l/day pregnant mouse body weight 30 g human respiratory volume 28,800 l/day <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1216">guinea</a></span> pig body weight 500 g dog respiratory volume 9,000 l/day rhesus <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5895">monkey</a></span> body weight 2.5 kg <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5895">monkey</a></span> respiratory volume 1,150 l/day <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1585">rabbit</a></span> body weight (pregnant or not) 4 kg mouse <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/138"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/139">consumption</a></span></a></span> 5 ml/day beagle dog body weight 11.5 kg rat <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/597">water</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/138"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/139">consumption</a></span></a></span> 30 ml/day rat respiratory volume 290 l/day rat food <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/138"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/139">consumption</a></span></a></span> 30 g/day the equation for an ideal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1139">gas</a></span>, pv = nrt, is used to convert concentrations of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1139">gases</a></span> used in inhalation studies from units of ppm to units of mg/l or mg/m3. consider as an example the rat reproductive toxicity study by inhalation of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5261">carbon</a></span> tetrachloride (molecular weight 153.84) is summarized in pharmeuropa, vol. 9, no. 1, supplement, april 1997, page s9.  nv = prt = 300 x 10 atm x 153840 mg mol l atm k mol x 298 k = 46.15 mg24.45 l = 1.89 mg/l-6-1-1-10082.  the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> 1000 l = 1 m3 is used to convert to mg/ m3.   18 part ii: impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/831">maintenance</a></span>) pde for tetrahydrofuran ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> having reached step 4 of the ich process at the ich steering committee meeting  on 12 september, 2002 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/150">incorporated</a></span> into the core <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> in november 2005, this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for  adoption to the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties to ich   the ich q3c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> reached step 5 in december of 1997. it had been agreed by the members of the expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group (ewg) that the permissible daily exposure (pde) could be modified if reliable and more relevant toxicity data was brought to the attention of the group. in 1999, a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/831">maintenance</a></span> agreement was instituted and a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/831">maintenance</a></span> ewg was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formed</a></span>. the agreement provided for the re-visitation of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> pdes and allowed for minor changes to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> that included the existing pdes. it was also agreed that new <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> and pdes could be added based upon adequate toxicity data. the ewg visited new toxicity data for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> tetrahydrofuran (thf) late last year and earlier this year. the data in review was the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/667"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1745">published</a></span></a></span> by the u. s. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicology</a></span> program (ntp) that consisted of data from several mutagenicity studies and two carcinogenicity studies in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodents</a></span> via the inhalational route of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8542">administration</a></span>. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> was sent to the members of the ewg for their analysis. animal toxicity <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5651">genetic</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicology</a></span> studies were conducted in salmonella typhimurium, chinese hamster ovary cells, drosophila melanogaster, mouse bone marrow cells and mouse <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3701">peripheral</a></span> blood cells. the in vitro studies were conducted with and without exogenous metabolic activation from induced s9 liver <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6111">enzymes</a></span>. with the exception of an equivocal small increase above baseline in male mouse erythrocytes, no positive findings were found in any of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5651">genetic</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicology</a></span> studies. groups of 50 male and 50 female rats were exposed to 0, 200, 600, or 1,800 ppm tetrahydrofuran by inhalation, 6 hours per day, 5 days per week, for 105 weeks. identical exposures were given to groups of 50 male and 50 female mice. under the conditions of the studies, there was some <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4434">evidence</a></span> of carcinogenic activity of thf in male rats due to increased incidences of adenoma or carcinoma (combined) of the kidney. there was clear <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4434">evidence</a></span> of carcinogenic activity of thf in female mice due to increased incidences of hepatocellular adenomas and carcinomas. no <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4434">evidence</a></span> for carcinogenicity was found in female rats and male mice. pde for tetrahydrofuran 19  using the lowest thf exposure in the most sensitive specie, the male rat at 200 ppm was used for the pde calculation.  ppm 720mg/day 7.2 101000 x 7.2limitmg/day 7.1651 x 10 x 1 x 10 x 550 x 71.65pdemg/kg 65.170.425290 x 0.105dosedaily mg/l 0.1057 x 245 x 6 x 0.59dosing continuousfor mg/l 59.0mg/m 8.89524.4572.10 x 200ppm 2003  conclusion: the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">former</a></span> pde for this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> was greater than 50 mg/day (121 mg/day) and thf was placed in class 3. the newly calculated pde for tetrahydrofuran based upon chronic toxicity/carcinogenicity data is 7.2 mg/day, therefore, it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> that tetrahydrofuran be placed into class 2 in table 2 in the ich impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. this is also the appropriate class for thf because this class <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contains</a></span> those <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> that are non-genotoxic carcinogens and thf has been demonstrated to be a non-genotoxic carcinogen in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodents</a></span>.  20 part iii: impurities : <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/831">maintenance</a></span>) pde for n-methylpyrrolidone (nmp) ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> having reached step 4 of the ich process at the ich steering committee meeting  on 12 september 2002 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/150">incorporated</a></span> into the core <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> in november 2005, this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for  adoption to the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties to ich (two mistyping corrections in the first calculation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formula</a></span> have been given  on october 28, 2002  this version is corrected)  the ich q3c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> reached step 5 in december of 1997. it had been agreed by the members of the expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group (ewg) that the permissible daily exposure (pde) could be modified if reliable and more relevant toxicity data was brought to the attention of the group. in 1999, a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/831">maintenance</a></span> agreement was instituted and a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/831">maintenance</a></span> ewg was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formed</a></span>. the agreement provided for the re-visitation of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> pdes and allowed for minor changes to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> that included the existing pdes. it was also agreed that new <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> and pdes could be added based upon adequate toxicity data. the ewg received new toxicity data for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> n-methylpyrrolidone late last year. it had been provided to the fda by the nmp <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1201">producers group</a></span>. it was a 2-
year chronic feeding study in rats performed by e.i. dupont de nemours & co (unpublished data). the data was sent to the members of the ewg for their analysis. at the time, that data appeared to be the best available upon which to make a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> to the steering committee regarding a change in the status of nmp. at the last ich meeting, february 28 to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1813">march</a></span> 2, 2000, i briefed the steering committee on the results of the ewgs analysis and its consensus <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span>. the consensus was to remove nmp from class 2 (pde of 48.4 mg/day) and place it into class 3 with a new pde of 207 mg/day. shortly thereafter, members of the ewg provided additional comment and data from which lower pdes could be determined. the following paragraphs <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contain</a></span> an analysis of an appropriate and more sensitive study from which to calculate a new pde. animal toxicity the following <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2228">paper</a></span> was used for the calculation of the pde for nmp: effects of prenatal exposure to n-methylpyrrolidone on postnatal development and behaviour in rats, hass u. et al., neurotoxicol. teratol.: 1994, 16, (3), 241-249. wistar rats were exposed by inhalation to 150ppm nmp for 6 hours/day, daily from days 7-20 of gestation and were then allowed to litter. no maternal toxicity was detected and litter size was unaffected by treatment. no physical abnormalities were described. the offspring were reduced in weight, the difference being statistically significant up to week 5 after <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2029">birth</a></span>. pre-weaning development was impaired as was higher cognitive function related to solving of difficult tasks. 
basal function of the cns was normal and there were no effects on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5102">learning</a></span> of low grade tasks. a noel was not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span>. pde for n-methylpyrrolidone (nmp) 21  ppm 530mg/day 5.3101000 x 5.3limit5 x 5 x 1 x 10 x 550 x 133.58pdemg/kg 133.580.33290 x 0.152dosedaily mg/l 0.152246 x 0.608dosing continuousfor mg/l 608.0mg/m 608.1624.4599.13 x 150ppm 1503 conclusion: this study was chosen because of the toxicity endpoint that was seen, that is, the effect of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> on the function of the developing nervous system in utero. this is a potentially serious toxicity since we do not know if it is a permanent effect or if it is reversible. we are not sure if this delayed development could be due to the lower body weight of the pups. however, the ewg has decided to be 
cautious in its <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1482">interpretation</a></span> and in its safety <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span>. the ewg members thus <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommend</a></span> that n-methylpyrrolidone should be kept in class 2 in table 2 in the ich impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. a new pde and limit as described above should also be declared for this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span>. class 2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contains</a></span> those <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> that have significant toxicities such as neurotoxicity, non-genotoxic carcinogenicity, teratogenicity etc., and should be limited in their use up to the pde limits listed in the table.   22 part iv: impurities : <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> (<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/831">maintenance</a></span>) pde for cumene ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> having reached step 4 of the ich process and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/150">incorporated</a></span> into the core <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on 4 february 2011, this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for  adoption to the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties to ich  introduction cumene [synonyms: cumol; isopropylbenzene; isopropylbenzol; (1-methyl/ethyl)benzene; 2-phenylpropane] is listed in the ich q3c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> in class 3, 
i.e., as a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> with low toxicity. a summary of the toxicity data used by the ewg to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> a permitted daily exposure (pde) value for cumene at the time when the ich q3c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> was signed off at step 2 in november 1996 is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/667"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1745">published</a></span></a></span> in connelly et al. (1).  according to this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">report</a></span> from the ewg no data from carcinogenicity studies with cumene were available. regarding genotoxicity data cumene was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> negative in an ames <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> and in saccaromyces cerevisiae and positive in in vitro uds and cell transformation assays using mouse embryo cells. calculation of a pde value was 
based on a rat toxicity study <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/667"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1745">published</a></span></a></span> in 1956. female wistar rats were given cumene at doses of 154, 462 and 769 mg/kg by gavage 5 days/week for 6 months. no histopathological changes but slight increases in kidney weights at the two higher doses were <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> suggesting a noel of 154 mg/kg. it was concluded that the pde for cumene is 55.0 mg/day i.e., cumene is a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> with low toxicity to be listed in class 3. (1) meanwhile new toxicity data have been <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/667"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1745">published</a></span></a></span> including results from ntp 2-year inhalation studies showing that cumene is carcinogenic in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodents</a></span>. (2) a reappraisal 
of the pde value of cumene according to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/831">maintenance</a></span> agreement from 1999 is therefore initiated. for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> a revised pde value in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> the 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> approaches (modifying factors, concentration conversion from ppm to mg/l, values for physiological factors) as described in detail in connelly et al. (1) were used. genotoxicity cumene was not mutagenic in s. typhimurium strain ta97, ta98, ta100, or ta1535, when <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> with and without liver s9 activation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6111">enzymes</a></span>. cumene induced small, but significant, increases in micronucleated polychromatic erythrocytes in bone marrow of male rats treated by intraperitoneal injection. in contrast, no increase in micronucleated erythrocytes was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3701">peripheral</a></span> blood of male (up to 1000 ppm) or female (up to 500 ppm) mice exposed to cumene by inhalation for 3 months. (2) p53 and k-ras mutations were found in 52% and 87% of lung neoplasms in exposed mice compared to 0% and 14% in the chamber controls, respectively. this pattern of mutations identified in the lung tumors suggests that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6260">dna</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/497"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/499">damage</a></span></a></span> and genomic instability may be contributing factors to the development of lung <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5104">cancer</a></span> in mice. (3) 
however, the overall genotoxic profile does not provide sufficient <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4434">evidence</a></span> for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">direct</a></span> 
mutagenic mode of action of cumene or its metabolites as the primary cause in tumorigenesis. (2) pde for cumene 23 carcinogenicity f344 rats were exposed to concentrations of 250, 500, or 1000 ppm of cumene in air by inhalation 6h/day, 5 days/week for 2 years. increased incidences of respiratory epithelial adenoma in the nose and renal tubule adenoma or carcinoma (combined) in males at all dose levels. increased incidences of respiratory epithelium adenoma in the nose in females at all dose levels. (2) molecular weight of cumene: 120.19 loel 250 ppm (a noel for carcinogenic effects was not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span>) 
 mg/l .231mg/m 1229 = 24.45120.19 x 250 = ppm 250   mg/l 0.22 = 7x 245 x 6 x 1.23 = dosing continuousfor    mg/kg/day 150 = kg 0.425day l 290 x l mg 0.22 = dosedaily -1-1  rat respiratory volume: 290 l day-1 rat body weight: 0.425 kg 
 
 mg/day 1.50 = 10x 10 x 1 x 10 x 550 x 150 = pde  f1 = 5 to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> for extrapolation from rats to humans f2 = 10 to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> for differences between individual humans f3 = 1 because long duration of treatment (105 weeks) 
f4 = 10 because oncogenic effect was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> 
f5 = 10 because a noel was not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> 
 ppm 150 = 101000 x 1.5 =limit    pde for cumene 24 b6c3f1 mice were exposed to concentrations of 125, 250, or 500 ppm (females) or 250, 500, or 1000 ppm (males) of cumene in air by inhalation 6h/day, 5 days/week for 2 years. increased incidences of alveolar/bronchiolar neoplasms in males and females at all dose levels. incidences of hepatocellular adenoma or carcinoma (combined) showed a dose-related increase in female mice. (2) loel 125 ppm (female mice)  mg/l 0.61mg/m 614 = 24.45120.19 x 125 = ppm 125   mg/l 0.11 = 7x 245 x 6 x 0.61 = dosing continuousfor    mg/kg/day 169 = kg 0.028day l 43 x l mg 0.11 = dosedaily -1-1  
mouse respiratory volume: 43 l day-1 mouse body weight: 0.028 kg  
 mg/day 0.70 = 10x 10 x 1 x 10 x 1250 x 169 = pde  f1 = 12 to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> for extrapolation from mice to humans f2 = 10 to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> for differences between individual humans f3 = 1 because long duration of treatment (105 weeks) f4 = 10 because oncogenic effect was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> f5 = 10 because a noel was not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> 
 ppm 70 = 101000 x 0.7 =limit   conclusion the main carcinogenic effects in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5874">rodent</a></span> studies can be related to the inhalation route of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8542">administration</a></span> (respiratory and olfactory tissues) and may therefore not be 
relevant for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> in (mainly) orally applied pharmaceuticals. however, pde for cumene 25 systemic carcinogenic effects were also <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> (kidney in male rats, liver in female mice) and the use of the ntp study data for calculation of a pde is therefore 
considered appropriate.  the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">former</a></span> pde for this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvent</a></span> was greater than 50 mg/day (55 mg/day) and cumene was placed in class 3. the newly calculated pde for cumene based upon carcinogenicity data is 0.7 mg/day, therefore, it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> that cumene be placed into class 2 in table 2 in the ich impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>.  references 1. connelly jc, hasegawa r, mcardle jv, tucker ml. ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>. pharmeuropa (suppl) 1997;9:57. 2. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicology</a></span> and carcinogenesis studies of cumene (cas no. 98-82-8) in f344/n rats and b6c3f1 mice (inhalation studies). natl toxicol program tech rep ser 2009;542;nih 09-5885. 3. hong hhl, ton tvt, kim y, wakamatsu n, clayton np, chan pc et al. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5651">genetic</a></span> alterations in k-ras and p53 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5104">cancer</a></span> genes in lung neoplasms from b6c3f1 mice exposed to cumene. toxicol pathol, 2008;36:720-6. </body><html>